GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 109,000 shares, an increase of 142.8% from the May 31st total of 44,900 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 1,060,000 shares, the short-interest ratio is presently 0.1 days.
GeoVax Labs Trading Down 10.3 %
Shares of GOVX stock opened at $3.19 on Friday. The firm has a 50-day moving average of $1.76 and a 200-day moving average of $2.72. GeoVax Labs has a one year low of $1.09 and a one year high of $10.24.
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. On average, sell-side analysts forecast that GeoVax Labs will post -7.41 EPS for the current year.
Hedge Funds Weigh In On GeoVax Labs
Wall Street Analyst Weigh In
Separately, HC Wainwright lifted their target price on shares of GeoVax Labs from $8.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th.
Read Our Latest Report on GOVX
About GeoVax Labs
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Recommended Stories
- Five stocks we like better than GeoVax Labs
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What does consumer price index measure?
- MarketBeat Week in Review – 6/24 – 6/28
- Comparing and Trading High PE Ratio Stocks
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.